Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University (ARU), shared his recent article on LinkedIn:
“Thanks to an amazing team and remarkable drugs, an Fc-enhanced CTLA-4 and anti-PD1, showing an impressive response rate and duration of response in heavily pre-treated sarcoma at Agenus, with special thanks to Robin Jones, Breelyn Wilky, Joseph Grossman and Steven O’Day.”
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
Authors: Breelyn A. Wilky, et al.
